176 related articles for article (PubMed ID: 27633825)
1. Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study.
Costa L; Caso F; Del Puente A; Di Minno MN; Peluso R; Scarpa R
J Rheumatol; 2016 Dec; 43(12):2149-2154. PubMed ID: 27633825
[TBL] [Abstract][Full Text] [Related]
2. Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis.
Luo X; Deng C; Fei Y; Zhang W; Li Y; Zhang X; Zhao Y; Zeng X; Zhang F
Semin Arthritis Rheum; 2019 Feb; 48(4):626-631. PubMed ID: 29929736
[TBL] [Abstract][Full Text] [Related]
3. DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort.
Lindqvist U; Wernroth ML; Husmark T; Larsson P; Geijer M; Teleman A; Theander E; Alenius GM
Clin Exp Rheumatol; 2017; 35(6):936-942. PubMed ID: 28628468
[TBL] [Abstract][Full Text] [Related]
4. Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping.
Stekhoven D; Scherer A; Nissen MJ; Grobéty V; Yawalkar N; Villiger PM; Möller B;
Clin Rheumatol; 2017 Sep; 36(9):2035-2043. PubMed ID: 28432523
[TBL] [Abstract][Full Text] [Related]
5. Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.
Chan MJ; Wen YH; Huang YB; Chuang HY; Tain YL; Lily Wang YC; Hsu CN
J Clin Pharm Ther; 2018 Apr; 43(2):256-264. PubMed ID: 29119581
[TBL] [Abstract][Full Text] [Related]
6. High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study.
Behrens F; Rech J; Thaçi D; Zinke S; Rothnie KJ; Oefner Daamen C; Leipe J
Mod Rheumatol; 2022 Jan; 32(1):87-95. PubMed ID: 32856975
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and Medication Pattern Change of Psoriatic Diseases in Taiwan from 2000 to 2013: A Nationwide, Population-based Cohort Study.
Wei JC; Shi LH; Huang JY; Wu XF; Wu R; Chiou JY
J Rheumatol; 2018 Mar; 45(3):385-392. PubMed ID: 29335350
[TBL] [Abstract][Full Text] [Related]
8. Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.
Fagerli KM; Kearsley-Fleet L; Mercer LK; Watson K; Packham J; Symmons DPM; Hyrich KL
Rheumatology (Oxford); 2019 Jan; 58(1):80-85. PubMed ID: 30137485
[TBL] [Abstract][Full Text] [Related]
9. Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis.
Allard A; Antony A; Shaddick G; Jadon DR; Cavill C; Robinson G; Korendowych E; McHugh N; Tillett W
Rheumatology (Oxford); 2019 Feb; 58(2):269-273. PubMed ID: 30247726
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015.
Lee MP; Lii J; Jin Y; Desai RJ; Solomon DH; Merola JF; Kim SC
Arthritis Care Res (Hoboken); 2018 May; 70(5):791-796. PubMed ID: 28804988
[TBL] [Abstract][Full Text] [Related]
11. Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study.
Ballegaard C; Højgaard P; Dreyer L; Cordtz R; Jørgensen TS; Skougaard M; Tarp S; Kristensen LE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):592-599. PubMed ID: 28772007
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of Psoriasis Arthritis Taking into Account New Treatment Options].
Ryser C; Ciurea A
Praxis (Bern 1994); 2018; 107(21):1147-1153. PubMed ID: 30326810
[TBL] [Abstract][Full Text] [Related]
13. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis.
Lubrano E; Scriffignano S; Perrotta FM
Expert Rev Clin Immunol; 2019 Dec; 15(12):1303-1312. PubMed ID: 31652079
[No Abstract] [Full Text] [Related]
14. Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study.
Hellgren K; Ballegaard C; Delcoigne B; Cordtz R; Nordström D; Aaltonen K; Gudbjornsson B; Love TJ; Aarrestad Provan S; Sexton J; Zobbe K; Kristensen LE; Askling J; Dreyer L
Rheumatology (Oxford); 2021 Aug; 60(8):3656-3668. PubMed ID: 33401297
[TBL] [Abstract][Full Text] [Related]
15. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
Gossec L; Coates LC; de Wit M; Kavanaugh A; Ramiro S; Mease PJ; Ritchlin CT; van der Heijde D; Smolen JS
Nat Rev Rheumatol; 2016 Dec; 12(12):743-750. PubMed ID: 27829672
[TBL] [Abstract][Full Text] [Related]
16. Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-α inhibitors.
Tsuruta N; Narisawa Y; Imafuku S; Ito K; Yamaguchi K; Miyagi T; Takahashi K; Fukamatsu H; Morizane S; Koketsu H; Yamaguchi M; Hino R; Nakamura M; Ohyama B; Ohata C; Kuwashiro M; Sato T; Saito K; Kaneko S; Yonekura K; Hayashi H; Yanase T; Morimoto K; Sugita K; Yanagihara S; Kikuchi S; Mitoma C; Nakahara T; Furue M; Okazaki F
J Dermatol; 2019 Mar; 46(3):193-198. PubMed ID: 30628100
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF Therapy and the Risk of Malignancies and Infections in Inflammatory Rheumatic Diseases - Our Experience.
Pap M; Sapina I; Laktašić Žerjavić N; Žagar I; Kovač Durmiš K; Kalebota N; Kovačević P; Caktaš IL; Dekleva V; Birkić D; Kolar Mitrović H; Perić P
Psychiatr Danub; 2021; 33(Suppl 4):625-631. PubMed ID: 34718291
[TBL] [Abstract][Full Text] [Related]
18. The current status and unmet needs in the management of psoriatic arthritis: Viewpoint from physicians in Taiwan.
Li TH; Liao HT; Huang YF; Shen YC; Chiu YC; Chen WS; Chen MH; Tsai CY; Chang DM
J Formos Med Assoc; 2018 May; 117(5):404-412. PubMed ID: 28552625
[TBL] [Abstract][Full Text] [Related]
19. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study.
Ogdie A; Haynes K; Troxel AB; Love TJ; Hennessy S; Choi H; Gelfand JM
Ann Rheum Dis; 2014 Jan; 73(1):149-53. PubMed ID: 23264338
[TBL] [Abstract][Full Text] [Related]
20. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
Queiro R; Cañete JD; Montilla C; Abad M; Montoro M; Gómez S; Cábez A;
Arthritis Res Ther; 2017 Mar; 19(1):72. PubMed ID: 28356155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
